Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study
Background Information is lacking regarding long-term survival and predictive factors for mortality in patients with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and undergoing invasive mechanical ventilation. We aimed to estimate 180-day mortality of patients with COVID-19 requiring invasive ventilation, and to develop a predictive model for long-term mortality. Methods Retrospective, multicentre, national cohort study between March 8 and April 30, 2020 in 16 intensive care units (ICU) in Spain. Participants were consecutive adults who received invasive mechanical ventilation for COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected in positive testing of a nasopharyngeal sample and confirmed by real time reverse-transcriptase polymerase chain reaction (rt-PCR). The primary outcomes was 180-day survival after hospital admission. Secondary outcomes were length of ICU and hospital stay, and ICU and in-hospital mortality. A predictive model was developed to estimate the probability of 180-day mortality. Results 868 patients were included (median age, 64 years [interquartile range [IQR], 56–71 years]; 72% male). Severity at ICU admission, estimated by SAPS3, was 56 points [IQR 50–63]. Prior to intubation, 26% received some type of noninvasive respiratory support. The unadjusted overall 180-day survival rates was 59% (95% CI 56–62%). The predictive factors measured during ICU stay, and associated with 180-day mortality were: age [Odds Ratio [OR] per 1-year increase 1.051, 95% CI 1.033–1.068)), SAPS3 (OR per 1-point increase 1.027, 95% CI 1.011–1.044), diabetes (OR 1.546, 95% CI 1.085–2.204), neutrophils to lymphocytes ratio (OR per 1-unit increase 1.008, 95% CI 1.001–1.016), failed attempt of noninvasive positive pressure ventilation prior to orotracheal intubation (OR 1.878 (95% CI 1.124–3.140), use of selective digestive decontamination strategy during ICU stay (OR 0.590 (95% CI 0.358–0.972) and administration of low dosage of corticosteroids (methylprednisolone 1 mg/kg) (OR 2.042 (95% CI 1.205–3.460). Conclusion The long-term survival of mechanically ventilated patients with severe COVID-19 reaches more than 50% and may help to provide individualized risk stratification and potential treatments. Trial registration: ClinicalTrials.gov Identifier: NCT04379258. Registered 10 April 2020 (retrospectively registered).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Annals of intensive care - 11(2021), 1 vom: 02. Okt. |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
ARDS |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1186/s13613-021-00929-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045209332 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045209332 | ||
| 003 | DE-627 | ||
| 005 | 20230519155526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211005s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13613-021-00929-y |2 doi | |
| 035 | |a (DE-627)SPR045209332 | ||
| 035 | |a (SPR)s13613-021-00929-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Peñuelas, Oscar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term survival of mechanically ventilated patients with severe COVID-19: an observational cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Background Information is lacking regarding long-term survival and predictive factors for mortality in patients with acute hypoxemic respiratory failure due to coronavirus disease 2019 (COVID-19) and undergoing invasive mechanical ventilation. We aimed to estimate 180-day mortality of patients with COVID-19 requiring invasive ventilation, and to develop a predictive model for long-term mortality. Methods Retrospective, multicentre, national cohort study between March 8 and April 30, 2020 in 16 intensive care units (ICU) in Spain. Participants were consecutive adults who received invasive mechanical ventilation for COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected in positive testing of a nasopharyngeal sample and confirmed by real time reverse-transcriptase polymerase chain reaction (rt-PCR). The primary outcomes was 180-day survival after hospital admission. Secondary outcomes were length of ICU and hospital stay, and ICU and in-hospital mortality. A predictive model was developed to estimate the probability of 180-day mortality. Results 868 patients were included (median age, 64 years [interquartile range [IQR], 56–71 years]; 72% male). Severity at ICU admission, estimated by SAPS3, was 56 points [IQR 50–63]. Prior to intubation, 26% received some type of noninvasive respiratory support. The unadjusted overall 180-day survival rates was 59% (95% CI 56–62%). The predictive factors measured during ICU stay, and associated with 180-day mortality were: age [Odds Ratio [OR] per 1-year increase 1.051, 95% CI 1.033–1.068)), SAPS3 (OR per 1-point increase 1.027, 95% CI 1.011–1.044), diabetes (OR 1.546, 95% CI 1.085–2.204), neutrophils to lymphocytes ratio (OR per 1-unit increase 1.008, 95% CI 1.001–1.016), failed attempt of noninvasive positive pressure ventilation prior to orotracheal intubation (OR 1.878 (95% CI 1.124–3.140), use of selective digestive decontamination strategy during ICU stay (OR 0.590 (95% CI 0.358–0.972) and administration of low dosage of corticosteroids (methylprednisolone 1 mg/kg) (OR 2.042 (95% CI 1.205–3.460). Conclusion The long-term survival of mechanically ventilated patients with severe COVID-19 reaches more than 50% and may help to provide individualized risk stratification and potential treatments. Trial registration: ClinicalTrials.gov Identifier: NCT04379258. Registered 10 April 2020 (retrospectively registered) | ||
| 650 | 4 | |a Coronavirus disease 2019 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a ARDS |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Intensive care unit |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Invasive mechanical ventilation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mortality |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Noninvasive ventilation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a del Campo-Albendea, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a de Aledo, Amanda Lesmes González |e verfasserin |4 aut | |
| 700 | 1 | |a Añón, José Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Solís, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Mancebo, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Ballesteros, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Maseda, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Figueira, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a Algaba, Ángela |e verfasserin |4 aut | |
| 700 | 1 | |a Avilés, Juan Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Abad, Beatriz |e verfasserin |4 aut | |
| 700 | 1 | |a Canabal, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Abella, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Gordo, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a García, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Suarez, Jessica García |e verfasserin |4 aut | |
| 700 | 1 | |a Cedeño, Jamil |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Palacios, Basilia |e verfasserin |4 aut | |
| 700 | 1 | |a Manteiga, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Blancas, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Bardi, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Pestaña, David |e verfasserin |4 aut | |
| 700 | 1 | |a Lorente, José Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Muriel, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Frutos-Vivar, Fernando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of intensive care |d Heidelberg : Springer, 2011 |g 11(2021), 1 vom: 02. Okt. |w (DE-627)SPR031925561 |w (DE-600)2617094-2 |x 2110-5820 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:02 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13613-021-00929-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |b 02 |c 10 | ||